What should I do if I become resistant to Entrectinib? How to deal with it?

Entrectinib (Entrectinib) is a targeted therapy drug for specific gene fusion-positive tumors, but in some cases, patients may develop drug resistance, causing the drug to no longer effectively control tumor growth. In the face of drug resistance, patients and doctors need to adopt a series of strategies to deal with it, in order to prolong the treatment effect and improve the quality of life.

1. Confirm drug resistance: First, if the patient develops tumor progression or other adverse reactions within a period of time after entrectinib treatment, doctors will conduct a detailed evaluation to confirm whether drug resistance has occurred. This may involve tumor marker testing, imaging evaluation, etc.

2. Genomic analysis: For patients who develop drug resistance, genomic analysis can help understand the molecular mechanisms of tumor development. Analysis may reveal information such as genetic mutations and changes in signaling pathways that lead to drug resistance, thereby providing clues for adjusting treatment options.

3. Consider other treatment options: After resistance is confirmed, doctors will consider other treatment options. This may include trying other targeted therapies, chemotherapy, immunotherapy, etc. Based on the genomic analysis results, doctors can develop individualized treatment plans.

4. Combination therapy: Sometimes, combining entrectinib with other drugs may help slow the development of resistance. Combination therapy can interfere with multiple signaling pathways at the same time and improve the therapeutic effect.

5. Clinical trials: Participation in clinical trials may be a promising option for patients who develop drug resistance. Clinical trials may test new targeted therapy drugs, immunotherapy, chemotherapy, etc., providing patients with new treatment opportunities.

6. Refined monitoring and follow-up: Even if drug resistance occurs, regular medical monitoring and follow-up are still very important. Monitoring can help doctors understand the development of tumors and adjust treatment plans early.

7. Psychological support: Drug resistance can have a psychological and emotional burden on patients. When dealing with drug resistance, the provision of psychological support and mental health services is crucial to help patients cope with emotional distress.

8. Active lifestyle: Maintaining a positive attitude, eating a balanced diet, exercising appropriately, and socializing with family and friends can help patients stay physically and mentally healthy while facing treatment challenges.

9. Cooperate with doctors: Patients should maintain close cooperation with their doctors and actively communicate about treatment effects, adverse reactions, and any changes. Doctors can make timely adjustments and suggestions based on the patient's condition.

In summary, in the face of entrectinib resistance, patients and physicians should collaborate to develop a comprehensive treatment strategy. Genomic analysis, personalized treatment, clinical trials, etc. are all important means to deal with drug resistance. Although drug resistance is a challenge, with appropriate treatment adjustments and comprehensive support, patients can still find effective treatments and maintain a good quality of life.

Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.